ClinicalTrials.gg
RecruitingNCT06314880Updated Apr 3, 2024

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

A Phase 1 interventional study of Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose) and Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose) in Healthy Volunteers, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 3 Months to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Jul 2023, registered Mar 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
3 Months to 50 Years
Sex
All
01

Study summary

The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.

Read the detailed description

This is a Phase I, single center, randomized, double-blind, placebo-controlled clinical trial conducted in Guangxi Province, China. The purpose of this study is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity. Expected to include 300 subjects, divide them into 5 age groups of 18-50 years old, 6-17 years old, 2-5 years old, 6-23 months old, and 3-5 months old, and 2 dose groups, a total of 10 groups, with 30 people in each group. The experimental group and placebo control group are 20 people and 10 people, respectively.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Recombinant Meningococcal Group B Vaccine (E. Coli)
03

In context

Escherichia coli Infections

100 studies on the registry are indexed under Escherichia coli Infections; 21 are open to participants now.

This study's planned enrollment of 300 is above the median of 74 across 64 interventional studies indexed under Escherichia coli Infections.

Browse Escherichia coli Infections studies →

Lead sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is the lead sponsor of 22 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range from 3 months to 50 years old, legal guardian and/or individual can provide legal identification;
  • The subjects and/or their legal guardians have the ability to understand the research procedures, agree to participate in the study (and/or their legal guardians agree to the child's participation in the study), and sign an form;
  • The subjects and/or their legal guardians are able to participate in all planned follow-up visits;
  • On the day of enrollment, the axillary temperature was less than 37.3 ℃;
  • Standards for certain groups of people:
  • Subjects ≥ 2 years old: laboratory test indicators (as specified in the protocol) within the normal range, or those with abnormalities but no clinical significance (evaluated by clinical doctors);
  • Female participants of childbearing age: Agree to take effective measures within 6 months from enrollment to full vaccination.

Exclusion criteria

Exclusion Criteria:

  • Have received any Group B meningococcal vaccine in the past;
  • A history of invasive diseases caused by meningococcus or gonococci;
  • Pregnant or lactating women;
  • Have any history of severe allergies to vaccines or drugs in the past, such as allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura;
  • Suffering from serious heart disease, liver disease, kidney disease, congenital malformations, developmental disorders, and genetic defects (including but not limited to Down syndrome, moderate to severe thalassemia, etc.) that may interfere with the progress or completion of the study;
  • Diagnosed as having congenital or acquired immunodeficiency, or suspected of having serious chronic or systemic diseases that may interfere with the conduct or completion of the study, such as active tuberculosis, , , (HIV), syphilis infection, etc;
  • Individuals with encephalopathy, uncontrolled epilepsy, seizures, and other progressive neurological disorders, or a history or family history of mental illness;
  • Suffering from for intramuscular injection such as thrombocytopenia, any coagulation disorders, or receiving anticoagulant therapy;
  • Received therapy within 3 months prior to vaccination, such as continuous use of systemic therapy for more than 2 weeks, such as prednisone or similar drugs>5mg/day (note: local and inhaled/nebulized steroids can be used);
  • Asplenia or splenectomy, functional asplenia caused by any circumstances;
  • Subjects with hypertension (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg, suitable for adults);
  • Suffering from acute illness or in the acute phase of chronic illness, or using antipyretic, analgesic, and antiallergic drugs (such as acetaminophen, ibuprofen, aspirin, etc.) three days before the first dose of vaccination;
  • Within 7 days (≤ 7 days) prior to enrollment, received inactivated vaccines, and within 14 days (≤ 14 days) received ;
  • Has received blood or blood related products or immunoglobulin (hepatitis B immunoglobulin is acceptable) within 3 months prior to enrollment;
  • Premature infants (gestational age\<37 weeks), low birth weight infants (birth weight\<2500g), and infants with a history of abnormal labor (only applicable to the 3-5 month and 6-23 month age groups);
  • Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
  • Participating in or planning to participate in clinical trials of other drugs in the near future;
  • The researchers believe that there are any conditions in the subjects that may interfere with the evaluation of the research objectives.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    18-50 years old

    60 people per age group. The first 15 subjects in the 18-50 age group will serve as sentinels, with 10 in the experimental group and 5 in the control group.

    Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose) · Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose) · Biological: Placebo control

  • Experimental
    6-17 years old

    60 people per age group. Divided into high-dose group, low-dose group, and placebo group.

    Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose) · Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose) · Biological: Placebo control

  • Experimental
    2-5 years old

    60 people per age group. Divided into high-dose group, low-dose group, and placebo group.

    Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose) · Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose) · Biological: Placebo control

  • Experimental
    6-23 months old

    60 people per age group. Divided into high-dose group, low-dose group, and placebo group.

    Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose) · Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose) · Biological: Placebo control

  • Experimental
    3-5 months old

    60 people per age group. Divided into high-dose group, low-dose group, and placebo group.

    Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose) · Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose) · Biological: Placebo control

Interventions

  • BiologicalEscherichia coliStudies of Escherichia coliEscherichia coli pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

  • BiologicalEscherichia coliStudies of Escherichia coliEscherichia coli pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

  • BiologicalPlacebo control

    Placebo control. 20 people/group.

06

What researchers measure

Primary outcomes

  1. The incidence rate of all AEs within 0-30 days after each dose of vaccination

    All AEs occurrence within 0-30 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination)

    Time frame: within 0-30 days after vaccination

  2. The incidence rate of solicited AEs within 30 minutes after each dose of vaccination

    All solicited AEs occurrence within 30 minutes after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination)

    Time frame: within 30 minutes after vaccination

  3. The incidence rate of solicited AEs within 0-14 days after each dose of vaccination

    All solicited AEs occurrence within 0-14 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination)

    Time frame: within 0-14 days vaccination

  4. The incidence rate of unsolicited AEs within 0-30 days after each dose of vaccination

    All unsolicited AEs occurrence within 0-30 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination)

    Time frame: within 0-30 days vaccination

  5. The incidence rate of grade 3 and higher AEs within 0-30 days after each dose of vaccination

    All grade 3 and higher AEs occurrence within 0-30 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination)

    Time frame: within 0-30 days vaccination

07

Study locations

1 of 1 sites recruiting
  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
    Nanning, Guangxi 530028, China
    Recruiting
    • Lirong Huang · Contact+86-13978620932
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Mar 18, 2024
StartActual
Jul 22, 2023
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06314880
Responsible party
Sponsor
First posted
Mar 18, 2024
Start date
Jul 22, 2023
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Apr 3, 2024

Study contacts

Wenjian Fang
Contact
fangwenjian@zhifeishengwu.com
+86-18611630252
Lin Du
study chair · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Escherichia coli

Start the discussion